MEDGF (Medacta Group) Growth Rank: 10 (As of Aug. 25, 2026) — 11% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEDGF Medacta Group SA MEDGF
71 GF Score
Price $160.00
GF Value $90.91
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medacta Group Growth Rank?

Medacta Group MEDGF +90.68% 71 Growth Rank is 10 as of Aug. 25, 2026, which is 11% above its 10-year median of 9.00. GuruFocus rates MEDGF with a GF Score™ of 71/100 and a GF Value™ of $90.91 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Medacta Group has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

MEDGF vs ABT, SYK, MDT: Growth Rank Comparison

For the Medical Devices subindustry, Medacta Group's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medacta Group Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Growth Rank distribution charts can be found below:

* The bar in red indicates where Medacta Group's Growth Rank falls into.


MEDGF
71GF Score
Medacta Group SA MEDGF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Medacta Group (MEDGF) has a Growth Rank of 10 as of Aug. 25, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Medacta Group and its competitors. This is 11% above median its historical median of 9.00. Over the past decade, Medacta Group's Growth Rank has ranged from 9.00 to 10.00.
Is Medacta Group's Growth Rank too high?
Medacta Group's current Growth Rank of 10 is 11% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 9.00 to a high of 10.00. Overall, Medacta Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Growth Rank compare to ABT and SYK?
Medacta Group's Growth Rank of 10 can be compared against companies in the Medical Devices & Instruments industry. Historically, Medacta Group's own Growth Rank has ranged from 9.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Medacta Group and its competitors. Medacta Group's current Growth Rank is 10, which is 11% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (MEDGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $90.91, compared to a current price of $160.00 — trading 76% above its estimated fair value. The current Growth Rank is 10, which is 11% above median its 10-year median of 9.00. Medacta Group's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Medacta Group (MEDGF), the current Growth Rank is 10 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (MEDGF) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be overvalued. The current stock price of $160.00 is trading 76% above its estimated GF Value™ of $90.91. GuruFocus considers Medacta Group to be Significantly Overvalued.

Key valuation signals for MEDGF:

  • Growth Rank: 10 (11% above median its 10-year median of 9.00)
  • GF Value™: $90.91 vs. price of $160.00 (76% above fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
71GF Score

Get the complete analysis for MEDGF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$160.00
Price
$90.91
GF Value